The medical use of psychedelic substances (e.g. psilocybin, ayahuasca, lysergic acid diethylamide and 3,4-methylenedioxymethamphetamine) is attracting renewed interest, driven by a pressing need for research and development of novel therapies for psychiatric disorders, as well as promising results of contemporary studies. In this Viewpoint, we reflect upon t...
Back to table of contents Previous article Next article APA & MeetingsFull AccessSession on Psychedelics Sure to Be EnlighteningNick ZagorskiNick ZagorskiSearch for more papers by this authorPublished Online:2 Mar 2021https://doi.org/10.1176/appi.pn.2021.3.14AbstractLeaders in psychedelic research will discuss the therapeutic potential of psychedelic compoun...
It is tough to write about psychedelics without a few gratuitous puns. Regardless, Michael Pollan’s “How to Change Your Mind” is definitely “mind expanding” and deserves my “highest” recommendation. Published in 2019, this book comprehensively and presciently covers a topic of increasing interest: whether psychedelic agents can revolutionize mental health. P...
BackgroundPsychedelic compounds such as lysergic acid diethylamide (LSD), psilocybin, and 3,4-Methylenedioxymethamphetamine (MDMA) share a long and complex history with psychiatry. A half century ago, psychedelics were widely employed by psychiatrists in investigational and clinical settings, with studies demonstrating promising findings for their use in the...
Psychedelic Harm Reduction and Integration (PHRI) is a transtheoretical and transdiagnostic clinical approach to working with patients who are using or considering using psychedelics in any context. The ongoing discussion of psychedelics in academic research and mainstream media, coupled with recent law enforcement deprioritization of psychedelics and compas...
Mindfulness-based interventions and psychedelic-assisted therapy have been experimentally utilised in recent years as alternative treatments for various psychopathologies with moderate to great success. Both have also demonstrated significant post-acute and long-term decreases in clinical symptoms and enhancements in well-being in healthy participants. These...
This study examined how psychedelics reduced symptoms of racial trauma among black, indigenous, and people of color (BIPOC) subsequent to an experience of racism. A cross-sectional internet-based survey included questions about experiences with racism, mental health symptoms, and acute and enduring psychedelic effects. Changes in mental health were assessed ...
ObjectiveTo conduct a systematic review of modern-era (post-millennium) clinical studies assessing the therapeutic effects of serotonergic psychedelics drugs for mental health conditions. Although the main focus was on efficacy and safety, study characteristics, duration of antidepressants effects across studies, and the role of the subjective drug experienc...
Despite a politically vilified past, classical psychedelics, including lysergic acid diethylamide (LSD), psilocybin, and dimethyltryptamine (DMT), are experiencing a revival in scientific and clinical research. When used under the appropriate guidance and setting, these substances show promise for substantially improving well-being and reducing mental ill-he...
After a two-decade hiatus in which research on psychedelics was essentially halted, placebo-controlled clinical trials of psychedelic-assisted therapy for mental health conditions have begun to be published. We identified nine randomized, placebo-controlled clinical trials of psychedelic-assisted therapy published since 1994. Studies examined psilocybin, LSD...
Psychedelics (i.e., ketamine, methylenedioxymethamphetamine, psilocybin) have been effectively used globally for centuries to treat mental health and addiction issues. However, in the 1950s-1970s, a number of factors, including misuse, abuse, and poorly conceptualized and conducted clinical trials, caused the Federal Drug Administration to classify most of t...
Anderson et al.’s [[1]Anderson B.T. Danforth A. Daroff R. Stauffer C. Ekman E. Agin-Liebes G. et al.Psilocybin-facilitated group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study.Eclinical Med. 2020; https://doi.org/10.1016/j.eclinm.2020.100538Summary Full Text Full Text PDF Scopus (74) Google Scholar...
The Yale Manual for Psilocybin-Assisted Therapy of Depression provides researchers and therapists with methods, structure, and areas to consider regarding the use of psychedelic- assisted therapy in the treatment of Major Depressive Disorder (MDD). In particular, this manual illustrates a mode of utilizing Acceptance and Commitment Therapy (ACT) as a therape...
The Yale Manual for Psilocybin-Assisted Therapy of Depression provides researchers and therapists with methods, structure, and areas to consider regarding the use of psychedelic- assisted therapy in the treatment of Major Depressive Disorder (MDD). In particular, this manual illustrates a mode of utilizing Acceptance and Commitment Therapy (ACT) as a therape...
After a two-decade hiatus in which research on psychedelics was essentially halted, placebo-controlled clinical trials of psychedelic-assisted therapy for mental health conditions have begun to be published. We identified nine randomized, placebo-controlled clinical trials of psychedelic-assisted therapy published since 1994. Studies examined psilocybin, LSD...
Back to table of contents Previous article Next article Clinical & ResearchFull AccessPsychedelics for Psychiatric Disorders: More Research NeededNick ZagorskiNick ZagorskiSearch for more papers by this authorPublished Online:13 Apr 2020https://doi.org/10.1176/appi.pn.2020.4a14AbstractAPA’s Work Group on Biomarkers and Novel Treatments suggests that psychede...
ObjectiveThe authors provide an evidenced-based summary of the literature on the clinical application of psychedelic drugs in psychiatric disorders.MethodsSearches of PubMed and PsycINFO via Ovid were conducted for articles in English, in peer-reviewed journals, reporting on "psilocybin," "lysergic acid diethylamide," "LSD," "ayahuasca," "3,4-methylenedioxym...
Psychedelic-assisted psychotherapy is seeing a resurgence as a treatment approach for mental health disorders. It melds pharmacology and psychotherapy, using substances such as lysergic acid diethylamide (LSD) and psilocybin, under medical supervision, to treat conditions such as post-traumatic stress disorder (PTSD) and extreme depression.
Psychedelics are back in vogue. In popular culture, political legislation, and scientific research, we appear to be witnessing an early twenty-first century renaissance of the heady acid days of the 1960s. The success of Michael Pollan’s 2018 New York Times bestseller, How to Change Your Mind, the decriminalization of psilocybin-containing mushrooms in Denve...
